Compare KPRX & ELAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KPRX | ELAB |
|---|---|---|
| Founded | 1998 | 2020 |
| Country | United States | United States |
| Employees | 13 | 34 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 9.6M |
| IPO Year | N/A | N/A |
| Metric | KPRX | ELAB |
|---|---|---|
| Price | $2.75 | $1.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 50.9K | ★ 546.8K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.76 | $0.66 |
| 52 Week High | $3.78 | $15.00 |
| Indicator | KPRX | ELAB |
|---|---|---|
| Relative Strength Index (RSI) | 58.52 | 39.77 |
| Support Level | $2.57 | $1.65 |
| Resistance Level | $2.94 | $2.28 |
| Average True Range (ATR) | 0.14 | 0.19 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 65.61 | 2.29 |
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
PMGC Holdings Inc IS advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.